2026-07-09 | Letter to the editor: GLP‑1RAs for pouchitis in obesity: what the current study does not tell us
To the Editors, We read with interest the report by Desai and colleagues that GLP‑1 receptor agonists were associated with a lower risk of recurrent pouchitis in obese patients with an ileal pouch–anal anastomosis and a history of pouchitis.1 The findings open an important avenue for secondary prophylaxis. Several unaddressed aspects, however, may help shape future investigations. The authors speculate that microbial stabilization may contribute to the protective effect, yet no direct evidence from pouch microbiota was provided. GLP‑1RAs can alter gut transit time, bile acid composition, and antimicrobial peptide secretion,2,3 each of which might reshape the pouch ecosystem in unpredictable ways. Without metagenomic or metabolomic profiling, the proposed mechanism remains conjectural. Future studies should collect pouch aspirates or effluent for shotgun sequencing alongside targeted analysis of short‑chain fatty acids and bile acids to clarify how the microbial community responds to treatment. Another underexplored issue concerns pouch motor function. GLP‑1RAs delay gastric emptying, but their impact on pouch contractility, residual rectal activity, or anal sphincter coordination is unknown. Some patients may experience incomplete evacuation, chronic constipation, or bacterial overgrowth, effects that would not be captured by a simple reduction in antidiarrheal use. Prospective research using pouch emptying scintigraphy or high‑resolution anorectal manometry could identify which patients benefit and who might develop adverse motor effects.4
Open article ↗
2026-07-09 | Response to letter to the editor: “GLP-1RAs for pouchitis in obesity: what the current study does not tell us”
To the Editors, We thank Dr Zhu and colleagues for their thoughtful interest in our study and are pleased that it has prompted further discussion.1 We reported that the use of glucagon-like peptide-1 receptor agonist (GLP-1RA) was associated with a lower risk of recurrent pouchitis in patients with obesity and an ileal pouch–anal anastomosis (IPAA) with prior pouchitis. The authors raise 3 points, concerning mechanism, pouch motility, and nutrition, which we are pleased to address.2 First, we agree with Zhu et al. that we did not provide direct microbial evidence for the protective effect. We did, however, propose a biologically grounded rationale. Preclinical models show that GLP-1 signaling suppresses nuclear factor-κB activation and reduces tumor necrosis factor-α and interleukin-6.3,4 In addition, the peripouch fat depot is independently associated with chronic pouchitis, and its reduction may lessen local inflammatory and mechanical stress.5 Because the TriNetX database contains neither endoscopic nor microbiome data, these mechanisms remain hypotheses that we could not test directly. We agree that pouch aspirate sequencing with short-chain fatty acid and bile acid profiling would be valuable in future studies.
Open article ↗
2026-07-01 | Patients with Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-like Peptide-1 Receptor Agonist Therapy.
High bowel frequency after ileal pouch-anal anastomosis (IPAA) causes significant symptom burden. We aimed to evaluate the impact of GLP-1 receptor agonists (GLP1RAs) in this setting. We conducted a retrospective cohort study of patients with prior IPAA for ulcerative colitis who were treated with a GLP1RA (n=20). Daily bowel frequency at baseline and 12 weeks after GLP1RA initiation was assessed. We also assessed the proportion of patients achieving ≥30% reduction in bowel frequency and ≤8 bowel movements per day. Median daily bowel frequency decreased from 9.0 (IQR, 6.0-12.5) at baseline to 6.0 (IQR, 5.0-8.1) at the 12-week follow-up (p<0.01). Overall, 7 of 20 patients achieved a ≥30% reduction in bowel frequency, and 15 of 20 had ≤8 bowel movements per day. In this retrospective cohort, we provide further evidence for the potential role of GLP1RAs in the management of high bowel frequency after IPAA.
Open article ↗
